Navigation Links
Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
Date:5/11/2011

SAN DIEGO, May 11, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society (ATS) in Denver, Colorado.  The poster, titled "The LPA1 Antagonist, AM152, Is Efficacious in Mouse Models of Fibrosis," will be presented on Monday, May 16, from 8:15 to 10:45 a.m. MDT.

The LPA1 receptor is part of the lysophosphatidic acid signaling pathway.  Under pathological conditions, LPA1 is associated with a breakdown of the endothelial barrier and the stimulation of fibroblast recruitment, proliferation and transformation, resulting in excessive deposition of extracellular matrix proteins.  Studies have shown that the LPA1 receptor may play a role in several fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF).

"Our preclinical data demonstrate that AM152 reduces pro-fibrotic activity by fibroblasts in vitro and tissue fibrosis in numerous in vivo models," said Gretchen Bain, Ph.D., Executive Director of Biology.  "AM152 reduces fibrosis in multiple tissue types thus providing a strong rationale for clinical exploration in patients suffering from a variety of fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Our lead LPA1 program, AM152, is one of the cornerstones for Amira's future.  As previously disclosed, we look forward to initiating Phase 2a clinical studies in patients suffering from fibrotic disease in order to explore the therapeutic benefit of this compound."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.  Our team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.  For more information, visit www.amirapharm.com.

Media Contact
Ian Stone
Russo Partners
Tel: +1 619 528 2220
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
2. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
3. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
4. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
5. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
6. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
7. Visage Imaging Releases Amira 5.3
8. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
9. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
10. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
11. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... for the second quarter ending June 30, 2017. ... advanced stages of preparing for our pivotal Phase 3 ... Chaim Lebovits , President and Chief Executive Officer ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... third quarter of 2017. ... on or about October 27, 2017 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 18, 2017 , ... Mediaplanet today announces the launch of ... and highlighting the importance of proactive eye and ear health. The campaign focuses ... innovations in hearing aid technology. , In this issue, the American Speech-Language-Hearing ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, ... new charity drive to generate community support for efforts to educate the local population ... treatments for all types of cancer. , Each day in America, roughly 4,600 ...
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & ... assistance to communities in North-Central West Virginia, is embarking on a cooperative charity ... in the area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... planning assistance that serves communities throughout southern Florida, is working to support the ... assets to children from low income families. , The Take Stock In Children ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning firm that serves residential and commercial clients in the greater ... drive to raise community support for the fight against cancer. , Founded by ...
Breaking Medicine News(10 mins):